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ABSTRACT 
 
The Hedgehog signaling pathway is a central player in developmental transformation 
facilitating many cellular functions such as differentiation, proliferation and survival. 
Consequently, any alterations in this pathway results in cellular deficiencies leading to disease 
conditions especially cancer. Constitutive activation of the HH pathway responsible for 
initiation, maintenance or proliferation of neoplastic changes is usually a result of genetic 
mutations of the HH pathway components or mediated by epigenetic modifications directed 
aberrant expression of the pathway components. While the genetic factors accountable for 
aberrant activity of the pathway have been extensively studied, the epigenetic machinery behind 
the deregulation hasn’t been properly understood. The present study has been conducted to 
decipher the epigenetic regulatory mechanism controlling HH pathway in breast cancer. 
Elucidation of the detailed epigenetic system behind the mismanagement of this crucial pathway 
will highlight the significance of developmental pathways in tumorigenic states. A better 
knowledge regarding the epigenetic causal factors involved in deregulation of HH pathway will 
provide opportunities for devising novel strategies for inhibiting its activity and result in better 
therapeutic and clinical implications for cancer treatment.  
 
Keywords: Hedgehog, Signaling pathways, Breast Cancer, Epigenetics, Development  
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INTRODUCTION 
 
The organized and systematic processes of growth and differentiation during 
development depend upon well-orchestrated signal transduction pathways that effortlessly 
transform a single cell into a complex multicellular entity. The Hedgehog (HH) signaling 
functions as a central organizer in this embryonic developmental scheme. It plays a crucial role 
in cell proliferation, cell fate determination, epithelial-to-mesenchymal transitions and the 
rearrangement of cells by motility and adhesion changes thus affecting development from 
embryonic stage. The overall activity of the pathway is significantly curtailed after 
embryogenesis; however HH pathway is also known to participate in stem cell maintenance, 
tissue repair and regeneration in adult physiology. As emphasis is being given to better 
understanding of cellular signaling pathways and their role in normal physiology as well as 
disease conditions, HH signaling pathway with its participation in embryonic development as 
well as its synergistic association with other cellular pathways such as Wnt, NOTCH, RAS 
pathways, occupies a position of paramount significance in this scheme. Thus, HH pathway has 
become an essential component of cellular differentiation network by orchestrating cell 
development in a systematically efficient manner.   
Neoplastic cells twist the molecular program of the cell and utilize it for tumor growth 
and cancer metastasis. The basic mechanism underlying this disruption involves deregulation of 
cellular signaling pathways that maintain homeostatic balance between cell growth and cell 
death. Also, constitutive activation of oncogenic signaling pathways encourages malignant 
transformation by conferring selective advantageous properties of survival and proliferation on 
tumor cells. Given the strategic importance of HH signaling pathway in normal development and 
differentiation, it is usually seen that deregulation of this pathway results in a number of 
physiological disorders and in many instances, leads to development of aggressive and metastatic 
cancers such as gastrointestinal cancer, medulloblastoma, pancreatic cancer, etc. The 
uncontrolled activity of the HH pathway results in drastic molecular and physiological changes 
such as increased metastatic behavior, enhanced survival capability, increased proliferative 
capacity and promotion of tumor invasiveness. Thus, inspite of being a developmentally inclined 
pathway assisting in efficient growth and differentiation, HH signaling pathway is manipulated 
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to participate in malignant progress. Therefore, it becomes necessary to identify the causal 
factors and understand the molecular mechanism responsible for this transgression so as to 
effectively thwart the HH pathway from mediating neoplastic changes. 
Constitutive activation of the HH pathway in a wide variety of cancers is mediated either 
by up-regulation of HH ligands -- Sonic HH (SHH), Indian HH (IHH) and Desert HH (DHH) 
and pathway components -- Patched (PTCH), Smoothened (SMO), Suppressor of Fused (SUFU), 
GLI or by genetic and epigenetic modifications in the pathway. Genetic alterations of the HH 
pathway components such as inactivating loss-of-function mutations in PTCH and SUFU, 
activating gain-of-function mutations in SMO and missense mutations in GLI1 and GLI3 has 
been largely documented. However, in recent years it has been increasingly evident that 
epigenetic modifications play an equally important role in deregulation of HH pathway as their 
genetic counterparts. Promoter DNA hypermethylation and transcriptional silencing of HH 
pathway components such as PTCH, SUFU, as well as transcriptional activation of SHH and 
GLI1 via loss of methylation are some of the prominent epigenetic changes in the HH pathway 
leading to its aberrant activation. It is thus clear that both epigenetic and genetic mechanisms 
work in tandem to silence the transcription of key components of the HH pathway and disrupt its 
normal activity, leading to malignant transformation and tumorigenesis. In the light of 
involvement of epigenetic changes in deregulation of HH pathway, the present study was 
designed to investigate the epigenetic regulatory mechanism controlling HH pathway in breast 
cancer. A comparative analysis of the gene expression profile of the different HH pathway 
components – SHH, PTCH, SMO and GLI1 after treatment with epigenetic drugs and 
modulators will be done. The project will help to shed light on the molecular mechanisms that 
force these developmentally inclined signaling pathways into over-riding the cellular balance and 
initiating tumorigenic progress and proliferation. The study will also be helpful in formulating 
novel strategies to inhibit the HH pathway in many aggressive and therapeutically challenging 
cancers. Targeting the epigenetic machinery behind HH pathway will have significant clinical 
implications resulting in novel and more effective cancer therapeutics. 
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REVIEW OF LITERATURE 
 
Hedgehog Signaling Pathway-An Overview: 
Hedgehog (HH) was first discovered by Christiane Nusslein-Volhard and Eric Wieschaus 
in fruit flies of the genus Drosophila as a segment polarity gene that regulates cuticle patterns in 
drosophila embryos. The pathway is thus named after this polypeptide signaling ligand. Like any 
typical signaling pathway, HH pathway is a highly coordinated system consisting of signaling 
ligand, receptor, effectors and downstream target genes along with host of assistant modulators. 
The mammalian HH family consists of three members -- Sonic HH (SHH), Indian HH (IHH) and 
Desert HH (DHH) (Hatsell and Frost, 2007). The functional specificity of the three variants is 
slightly different, e.g. DHH is involved in germ cell development in males, IHH facilitates long-
bone growth and cartilage development and SHH participates in establishing left-right body 
asymmetry, central nervous system development, somite patterning, eye development and limb 
patterning (St-Jacques et al., 1999; Beachy et al., 2010). However, all the three ligands undergo 
similar autocatalytic cleavage and double lipid modifications to generate an active signal and 
perform similar biological interactions (Bian et al., 2007). 
The HH ligand reception system is composed of a 12-span transmembrane receptor 
protein -- Patched (PTCH) (Jiang and Hui, 2008). PTCH proteins are distantly related to 
Dispatch family members found in Drosophila and putative have a sterol sensing domain mostly 
for for suppression of SMO activity, thus indicating that HH pathway signal transduction is 
regulated by lipid modifications (Strutt et al., 2001). Smoothened (SMO) is a 7-span 
transmembrane protein -- of the G-protein-coupled receptor family and plays the role of signal 
transducer in the HH pathway by relaying the ligand induced signal to the downstream effectors 
and ultimately activating the target genes (Ruiz-Gomez et al., 2007). The five-zinc finger 
containing transcription factor GLI proteins, GLI1, GLI2 and GLI3 are the principal downstream 
effector molecules of HH signaling pathway. They share five highly conserved tandem C2-
H2DNA binding zinc-finger domains and histidine/cysteine linker sequence between zinc fingers 
that binds to consensus sequences on their target genes (Villavicencio et al., 2000). However, 
their mode of activity slightly varies from each other. GLI1 acts exclusively as a transcriptional 
activator; GLI2 and GLI3 are bi-functional transcription factors -- their full-length forms work as 
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transcriptional activators whereas removal of their C-terminal activation domains leads to 
transcriptional repression (Jacob and Briscoe, 2003; Ingham et al., 2011)(Fig. 1). 
In the absence of HH ligand, SMO is blocked by PTCH, GLI proteins are retained in the 
cytoplasm with other proteins such as the kinesin-like COSTAL2, the serine–threonine kinase 
Fused, and suppressor of Fused (SUFU). GLI1 is transcriptionally silent, GLI2 is phosphorylated 
by glycogen synthase kinase 3 (GSK3), Caesin kinase 1(CK1) and Protein Kinase A (PKA) and 
subsequently degraded by proteolysisand GLI3 is present mostly as a cleaved repressor thus 
resulting in transcriptional silencing of HH-GLI target genes (Katoh and Katoh, 2008). However, 
when the HH ligand binds to PTCH, it enables SMO translocates to the primary cilium and 
prevents the suppressive kinase action on GLI factors. As a result, GLI1 is activated 
transcriptionally, GLI2 becomes an activator; and GLI3 is no longer cleaved (Ruiz i Altaba et al., 
2007). Accumulation of GLI activators in the nucleus leads to increased expression of a number 
of HH target genes, prominent among them being  PTCH, GLI, insulin-like growth factor 2 
(IGF-2), platelet derived growth factor receptor α (PDGFR-α),Forkhead box proteins—(FOXA2, 
FOXC2, FOXE1, FOXF1, FOXL1, FOXP3), POU class 3 homeobox 1 (POU3F1), Runt-related 
transcription factor 2 (RUNX2), SRY (sex determining region Y)-box 13 (SOX13), and T-box 2 
(TBX2)for cell fate determination and cancer proliferation and invasion-related genes (Katoh 
and Katoh, 2008). 
 
Figure 1: A schematic overview of the HH signaling pathway 
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Hedgehog Signaling Pathway and its Multifaceted Role in Tumorigenesis: 
 HH signaling pathway is an important mediator of the development transition 
participating in myriad aspects of cellular growth and proliferation.  Hence, it is obvious that 
deregulation of the pathway will lead to abnormal changes in the normal homeostatic state of the 
cellular system resulting in pathophysiological conditions and most importantly neoplastic 
changes. Aberrantly active HH signaling pathway leads to initiation, proliferation and 
progression of cancer either by a ligand dependent or a ligand-independent manner (Kar et al., 
2012). In the ligand dependent manner, there are two approaches—firstly, autocrine pathway 
where HH ligand is over-expressed by tumor cells and act on neighboring cells to stimulate their 
proliferation. This type of mechanism is active in lung cancer, gastrointestinal cancer, pancreatic 
cancer, prostate cancer etc. The approach is more complicated and involves a paracrine model 
where HH ligand secreted from the epithelium stimulates the underlying stromal compartment to 
undergo neoplastic changes. Ovarian cancer and colorectal cancer has been to exhibit the 
paracrine mechanism (Teglund and Toftgard, 2010). 
 In the ligand-independent induction of HH pathway, genetic and epigenetic modifications 
play a more crucial role. Genetic alterations of the HH pathway components such as inactivating 
loss-of-function mutations in PTCH and SUFU, activating gain-of-function mutations in SMO 
and missense mutations in GLI1 and GLI3 has been largely documented in a wide variety of 
cancer. However, epigenetic modifications affecting HH pathway deregulation has recently come 
into highlight. These epigenetic changes mainly involve promoter DNA hypermethylation of HH 
pathway components such as PTCH, SUFU, as well as transcriptional activation of SHH and 
GLI1 via loss of methylation. Promoter methylation of PTCH has been reported in case of breast 
cancer, ovarian dermoids and fibromas and also in gastric cancer. Similarly, Shahi et al., have 
reported higher expression of GLI1 in a subset of medulloblastoma and glioblastoma cell lines. 
The negative regulator of HH-GLI signaling--HH-interacting protein (HHIP) is also shown to be 
down-regulated by promoter hypermethylation in hepatocarcinoma. In another study by Wang et 
al., promoter hypomethylation of SHH is an important cause of gastric carcinogenesis. It is thus 
clearly evident that both genetic and epigenetic constraints are working in tandem to disrupt the 
HH pathway in cancer. 
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Figure 2: The different mechanisms that result in aberrant constitutive activation of the 
HH signaling pathway. HH signaling pathway is disturbed by both genetic alterations such 
as gain-of-function mutations, loss-of-function mutations, missense mutations, gene 
amplifications whereas DNA methylation and demethylation seem to be the principal 
causes of epigenetic regulation (Adapted from Kar et al., 2012, Experimental Cell Research). 
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Malfunctioning HH signaling encourages the transformation of normal cells into tumor 
phenotype by conferring selective advantageous properties of growth and survival on neoplastic 
cells (Fig 3). Constitutively active HH signaling increases tumorigenic properties such as 
increased metastatic behavior of cancer cells, enhances survival capability by up-regulating anti-
apoptotic mediators Bcl-2 and inhibiting apoptotic cell death, increasing the proliferative 
capacity by disrupting the cell cycle machinery and promoting tumor invasiveness by inducing 
Snail-mediated E-cadherin down-regulation. Moreover, HH pathway is synergistically linked 
with many other developmentally inclined pathways; hence it manipulates other oncogenic 
signaling such as K-Ras, p53 etc. and similar developmentally concerned pathways such as 
EGFR, Wnt/β-catenin, NOTCH, TGF-β, c-Jun N-terminal kinase pathways to participate in 
tumorigenic changes. One of the more devastating effects of persistent HH activation is its 
involvement in self-renewal, survival, migration, and metastasis of cancer stem cells, thus 
contributing to therapy resistance and cancer relapse after therapy.  
Aberrant HH pathway in Breast Cancer: 
Breast cancer is the most common neoplastic disease affecting women and is one of the 
leading causes of cancer related deaths for women in both developed and developing countries. 
The HH signaling pathway has been implicated in causing or contributing to the development of 
mammary gland cancer via its constitutive activation (Katano, 2005). Genetic causes such as 
inactivating mutations of PTCH1, activating missense mutations of SMO, loss of function 
mutations of SUFU are some of the more common factors encouraging development of breast 
cancer. A number of other genomic changes have also been implicated such as loss of the 
PTCH1 chromosomal region, gain of the 12q13.2–q13.3 chromosomal region encompassing 
GLI1 binding sites, (Naylor et al., 2005; Nessling et al., 2005)and a natural polymorphism in the 
regulatory C terminus of the PTCH coding region (C3944T; Pro1315-Leu)(Kasper et al., 2009). 
However, the primary factor responsible for aberrant activity of HH pathway is over-expression 
of the HH pathway ligand--SHH and the downstream transcriptional targets GLI and PTCH1 
(Hatsell and Frost, 2007). 
Epigenetic mechanisms are now considered as much more important regulators that 
sustain aberrant HH signaling in breast cancer initiation and progress. These modifications 
include silencing of PTCH by promoter methylation (Wolf et al., 2007), hypomethylation of 
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SHH promoter (Wang et al., 2006a) and promoter methylation of the negative regulator of the 
pathway, hedgehog interacting protein (Hip). The deregulation of the HH pathway results in 
increased tumor cell proliferation, providing enhanced survival and metastasic potential 
ultimately giving rise to neoplasia (Kasper et al., 2009). Over-expression of transcriptional 
repressor Bmi-1(B lymphoma Mo-MLV insertion region 1 homolog) is another important cause 
of breast cancer because the mammary gland stem cells are maintained in an immortal state. 
Additionally HH signaling interacts synergistically with other crucial developmentally concerned 
signaling pathways and pro-oncogenic factors to mediate cancer formation (Fig. 3).  
 
Figure 3: A schematic representation of the different molecular mechanisms by which constitutively active 
HH pathway mediates different types of cancer (Adapted from Kar et al., 2012, Experimental Cell Research). 
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OBJECTIVES OF THE PROJECT 
 
1. Study of the gene expression status of the different Hedgehog signaling pathway 
components - SHH, SMO, PTCH, GLI1 in MDA-MB-231 and MCF7 breast cancer cell 
lines. 
 
2. Study of the effect of various epigenetic modulators such as AZA (inhibitor of DNMT), 
SAM (co-factor in the methylation reaction), TSA and SFN (Histone deacetylase 
inhibitors), EGCG and Curcumin (Natural HH antagonists) on the survival and growth 
characteristics of MDA-MB-231 and MCF7 breast cancer cells.  
 
3. Comparative analysis of the effect of various epigenetic modulators on the expression of 
the different Hedgehog pathway components after treatment.  
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MATERIALS AND METHODS 
 
1. In vitro cell culture: 
Human breast carcinoma cell lines MCF-7 and MDA-MB-231 were cultured and 
maintained in Modified Eagle’s Medium (MEM) and Dulbecco’s Modified Eagle’s Medium 
(DMEM, Invitrogen) respectively supplemented with 10% (v/v) Fetal Bovine Serum (FBS, 
Invitrogen) and 100 IU/mL penicillin and 0.1 mg/mL streptomycin in a humified atmosphere 
of 5% CO2 at 37°C. 
 
2. Treatment with epigenetic drugs –AZA, SAM, TSA, SFN, EGCG, Curcumin: 
Stock solutions of AZA, TSA, SFN, EGCG and Curcumin (Sigma) were prepared in 
dimethylsulphoxide (DMSO, Sigma) whereas SAM (Sigma) was dissolved in milli-Q water. 
Cells were harvested by trypsinization and cell number was counted by haemocytometer. For 
determining the concentration of drug that inhibited cell proliferation by 50% (IC50), 5 X 10
3
 
cells per well were seeded in 96-well microtiter plate and after 24 h incubation, were treated 
with the epigenetic modulators at different concentrations (Table1) mixed in DMEM 
supplemented with 5% FBS. Control cells were treated with DMSO only. The cells were then 
incubated for 24 h. 
Table 1: Different concentrations of the various epigenetic drugs considered for MTT assay 
Drugs Concentrations 
AZA 5, 7.5, 10, 12.5, 15, 17.5, 20, 25 μM 
SAM 5, 7.5, 10, 12.5, 15, 17.5, 20, 25 μM 
TSA 50, 100, 150, 200, 300, 350, 400 nM 
SFN 5, 7.5, 10, 12.5, 15, 17.5, 20, 25 μM 
EGCG 50, 100, 150, 200, 250, 300, 350, 400 μM  
Curcumin 10, 20, 30, 40, 50, 60, 70 μM 
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3. Cell Viability Analysis by colometric MTT Assay:  
 The effect of the epigenetic drugs on cellular proliferation was assessed by 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT, Sigma) assay, using 
standard protocol. The MTT assay is based on the observation that the mitochondria in living 
cells can catalyze MTT molecules to a colorimetrically detectable dye. Briefly, the drug-
treated cells in each of the 96 wells were washed twice with PBS. 0.8 mg/mL MTT solution 
was prepared from stock MTT solution (5 mg/mL PBS, pH 7.2). 100 μL MTT solution was 
added to each well and incubated at 37º C for 4 h in dark. The supernatant was removed and 
100 µL of DMSO was added into each well to dissolve the formazan crystals. The 
absorbance was measured at 570 nm and results were expressed as the mean of three 
replicates as a percentage of control (taken as 100%).The extent of cytotoxicity was defined 
as the relative reduction of the optical density (OD), which correlated to the amount of viable 
cells in relation to cell control (100%). The absorbance was plotted in a graph and the IC50 
was calculated accordingly to decide the optimum dosage of the drugs for further studies. 
 
4.  Chromatin condensation analysis by Hoechst staining:  
 After treatment with epigenetic modulators at the IC50 concentration, cells were stained 
with Hoechst 33342 stain (1 mg/ml, Invitrogen) followed by incubation for 10 mins at 37
o 
C. 
Images were taken under UV filter using Epi-fluorescent Microscope (Olympus IX71) at 400 
X magnification with an excitation wavelength of 355-366 nm and an emission wavelength 
of 465-480 nm. Condensed nuclei were counted against total number of nuclei in the field, 
and the percentage of apoptotic nuclei were calculated and plotted graphically.  
 
5. Scratch and Migration Assay: 
The effect of various epigenetic modulators on the wound healing and cell migration was 
assessed by scratch and migration assay. Approximately 10
6 
cells were seeded onto 6-well 
plates and incubated for 24 h. A scratch was done with the help of a sterile tip, media was 
removed and then the cells were washed twice with PBS and then treated with the IC50 
values of the various epigenetic drugs. The cells were then incubated for 24 h and then 
images were taken using Epi-fluorescent Microscope (Olympus IX71) at 10X magnification. 
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6. Extraction of Total RNA:  
MCF-7 and MDA-MB-231 cell lines were treated with sub lethal dosages of the various 
epigenetic drugs for 24 h. After treatment for the required time, total RNA was extracted 
using the Trizol (Sigma) reagent according to the manufacturer’s instructions. The drug 
treated cells (5-10 X 10
6
 cells) were washed with 1 ml ice cold PBS, then trypsinized and 
then treated with 1 ml Trizol. 0.2 ml of chloroform (Sigma) (0.2 ml per 1 ml of TRI Reagent) 
was added to the tubes, shaken vigorously for 30 seconds by hand/vortex mixer and 
incubated at RT for 10 mins. The samples were centrifuged at 12,000 X g for 15 mins at 4° 
C. Following centrifugation, the mixture separates into lower red, phenol-chloroform phase, 
an interphase, and a colorless upper aqueous phase containing the RNA. The upper aqueous 
phase was removed without disturbing the interphase and collected in a fresh tube. 0.5 ml 
isopropyl alcohol (Sigma) per 1 ml of TRI Reagent was added to the tubes. The tubes were 
then incubated at RT for 10 minutes and then centrifuged at not more than 12,000 x g for 10 
minutes at 4° C. The supernatant was removed completely. The RNA precipitate, often 
invisible before centrifugation, forms a gel-like pellet on the side and bottom of the tube. The 
pellet was washed with 1ml of 75% ethanol per 1 ml of TRI Reagent. The samples were 
mixed by vortexing and centrifuged at no more than 7,500 x g for 5 minutes 4° C. The pellet 
was air-dried by keeping the RNA pellet containing tube opened in working bench for 15 
mins. The RNA was dissolved in 50 μl DEPC-treated water by passing solution a few times 
through a pipette tip. The RNA was stored at -20° C for further use or immediately processed 
for cDNA synthesis.  
 
7. Quantitative Estimation of RNA Concentration by Spectrophotometric Analysis:  
The concentration of the extracted total RNA was quantified by measuring the 
absorbance at 260 nm in a spectrophotometer (ELICO, BL 200 Bio Spectrophotometer, 
double beam) and calculated by using the formula as given below:  
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
 
 
 
 
14 | P a g e  
 
8. First strand cDNA synthesis:  
Total RNA (2 μg) was used for first strand cDNA synthesis by reverse transcription using 
RevertAidTM First Strand cDNA Synthesis Kit (Fermentas) in a thermocycler (Biorad). The 
RNA was incubated with 1 μl of oligo (dT)18 primers (100 μM, 0.2 μg/μl) and 12 μl of 
nuclease-free water at 65º C for 5 mins. The reaction was cooled on ice to allow the primers 
to anneal to the RNA, then spun down and placed on ice again after which the following 
components were added to the reaction in order; 4 μl of 5X Reaction Buffer, 1 μl of 
RibolockTM RNase inhibitor (20 U/μl), 2 μl of 10 mM dNTPs and 1.0 μL of RevertAidTM 
M-MuLV-Reverse Transcriptase (200 U/μl). The reagents were gently mixed and incubated 
for 1 h at 42º C. Heating at 70º C for 5 mins terminated the reaction and the synthesized 
cDNA was stored at –20º C for further use.  
 
9. Gene-specific semi-quantitative PCR for amplification of the desired genes:  
The PCR reaction mixtures, in a 25 μl volume, contained 17 μl of dH2O (Sigma), 2.5 μl 
of 1X PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, 
Sigma), 0.5 μl each of the forward and reverse primers (0.2 μM, Sigma) of SHH, PTCH, 
SMO, GLI1, 0.5 μl Taq DNA-polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was 
added. PCR amplifications were performed in a thermal cycler (Biorad) by initial 
denaturation at 94° C for 1 min, followed by 30 cycles of denaturation at 94° C for 20 secs, 
annealing at 58° C for 20 secs, and extension at 72° C for 30 secs, followed by an final 
extension step at 72° C for 5 mins. The constitutively expressed housekeeping gene, β-actin 
was used as a positive control to ensure high quality. RT-PCR products were then analyzed 
by 1% agarose gel electrophoresis containing ethidium bromide (0.05%). The primer 
sequences for the PCR reaction are shown in Table 2. 
 
10. Relative Gene Expression Analysis after drug treatment by Real-Time PCR: 
 Quantitative estimation of the expression of the MBD genes after drug treatment was 
done via real-time PCR analysis. qRT-PCR was performed using cDNA prepared from 1μg 
of total RNA prepared using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) 
and SYBR
®
 Green JumpStart™ Taq ReadyMix (Sigma) in the Realplex4Eppendorf system. 
The mRNA level was normalized to β-actin. The primer sequences are provided in Table 2. 
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Table 2: List of sequence and product length of the Real-Time PCR Primers 
Gene Primer sequence Tm Product 
 
 
 
 
 
SHH 
F 5’-- CCAAAGCGTTCAACTTGTCC--3’ 57.88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 bp 
R 5’—TTTAAGGAACTCACCCCCAA--3’ 56.24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PTCH 
F 5’—TCTCCAATCTTCTGGCGAGT—3’ 58.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 bp 
R 5’—TGGGATTAAAAGCAGCGAAC--3’ 56.71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SMO 
F 5’ – CAACCTCTTTGCGTTTCCTT—3’ 56.84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 bp 
R 5’—ACTCACTGCTCCTATCCCACTC—3’ 60.95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GLI1 
F 5’ – AGGGAGTGCAGCCAATACAG--3’ 59.75 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 bp 
R 5’—ATTGGCCGGAGTTGATGTAG--3’ 57.67 
β-ACTIN 
F 5’- CTGGAACGGTGAAGGTGACA -3’ 58.12 
140 bp 
R 5’- AAGGGACTTCCTGTAACAACGCA -3’ 58.35 
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RESULTS AND DISCUSSION 
 
1. Cell Viability Analyses by colometric MTT Assay 
Epigenetic modulators inhibit cell growth in MCF-7 and MDA-MB-231 breast cancer 
cell lines in a dose-dependent manner. 
 
The effect of the various epigenetic modulators -- AZA, SAM, TSA, SFN, EGCG and 
CR on the cell viability after 24 h treatment was assessed by colorimetric MTT assay. The 
different modulators have their own distinct effect on cell viability at different concentrations. 
The results obtained from MTT assay are given below (Fig.4 (a, b, c)). 
 
Figure 4(a): The effect of different concentrations of DNMT modulators – AZA and SAM after 24 h. 
  
Figure 4(b): The effect of different concentrations of HDAC inhibitors –TSA and SFN after 24 h. 
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Figure 4(c): The effect of different concentrations of Natural HH antagonist – EGCG & CR after 24 h. 
 
In general, cell survival levels declined progressively with increasing doses of all the 
epigenetic drugs in both the cell lines (Fig. 4(a, b, c). From this assay, IC50 values i.e. the 
concentration of drug which results in 50% cell viability for both cell lines is determined as 
follows (Table 3). 
Table 3: IC50 concentrations of epigenetic modulators used against MCF-7 and MDA-MB-231. 
Drug IC50 in MCF-7 IC50 in MDA-MB-231 
AZA 15 μM 15 μM 
SAM 15 μM 15 μM 
TSA 100 nM 150 nM 
SFN 10 μM 10 μM 
EGCG 200 μM 250 μM 
Curcumin 25 μM 25 μM 
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2. Chromatin condensation analysis after drug treatment by Hoechst staining  
Epigenetic modulators promote apoptotic cell death in MCF-7 and MDA-MB-231 cells. 
 
Nuclear chromatin condensation analysis of drug treated MCF-7 and MDA-MB-231 cells 
by Hoechst staining was performed to study the cytotoxic effect of the epigenetic modulators on 
the cell survival. Both the cell lines were treated with IC50 concentration of the epigenetic drugs 
for 24 h to study their effect on cell cycle and cell growth. It is observed that all the epigenetic 
modulators promote apoptotic cell death in cells as is evident form increased chromatin 
condensation which is a distinct characteristic of apoptotic cells. The results of Hoechst staining 
assay are given below (Fig. 5 (a, b)). 
 
Figure 5(a): Nuclear chromatin condensation in treated MCF-7 cells after 24 h.  
Panel [I] representative images of Hoechst 33342 stained nuclei,  
Panel [II] percentage of condensed nuclei represented graphically.  
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 Figure 5(b): Nuclear chromatin condensation in treated MDA-MB-231cells after 24 h.  
 
During apoptosis, the chromatin becomes inert, highly condensed, undergoes fragmentation 
and gets packaged into apoptotic bodies. The morphological changes induced by apoptosis can 
be visually detected by the blue-fluorescent Hoechst 33342 dye which brightly stains the highly 
condensed, dense chromatin of apoptotic cells in comparison to the chromatin of non-apoptotic 
cells. After treatment with the epigenetic modulators at specific concentrations—AZA (15 μM), 
SAM (15 μM), TSA (100 nM), SFN (10 μM), EGCG (200 μM) and CR (25 μM), the percentage 
of condensed nuclei are found to be 21.54%, 17.45%, 50.23%, 66.34%, 22.87% and 29.26% 
whereas controls cells exhibited only 5.23% of condensed cells (Fig. 5 (a), panel II). In case of  
MDA-MB-231 cells, the percentage of condensed nuclei were 28.36%, 18.73%, 48.45%, 
53.46%, 21.34% and 27.87% respectively for AZA, SAM, TSA, SFN, EGCG and CR whereas 
control cells exhibit 7.64% condensed nuclei (Fig. 5(b), panel II). The percentage of condensed 
nuclei is highest in TSA and SFN treated cells for both the cell lines, hence, TSA and SFN are 
seen to be highly effective in inducing apoptosis in breast cancer cells.  
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3. Flow Cytometry Analysis of the effects of epigenetic drugs on cell cycle (FACS)  
      Epigenetic modulators induce G2-M arrest and apoptosis in MCF-7 and MDA-MB-231 cells. 
In order to study the effect of the epigenetic modulators on the cell cycle and cell growth, 
flow cytometry based cell cycle analysis of MCF-7 and MDA-MB-231 cells after treatment for 
24 h with the epigenetic modulators was performed. There is an alteration in the cell cycle 
distributions in both the cell lines (Fig. 6(a, b)). In case of MCF-7, percentage of G1, S, G2/M and 
apoptotic cells is 41.2%, 10.7%, 9.6% and 8.5% respectively for untreated control cells. After 
treatment with AZA (15 μM), the percentage of G1, S, G2/M and apoptotic cells is found to be 
41.1%, 5.1%, 6.4% and 20.5% respectively. After treatment with SAM (15 μM), the percentage 
of G1, S, G2/M and apoptotic cells is found to be 38.5%, 12.3%, 5.3% and 8.9% respectively. 
Similarly, for TSA (100 nM) treatment, the percentage of G1, S, G2/M and apoptotic cells is 
observed to be 16.3%, 5.4%, 6.9% and 29.3% respectively w.r.t untreated cells. The percentage 
of G1, S, G2/M and apoptotic cells after treatment with SFN (10 μM) is seen to be 3.2%, 6.3%, 
2.9% and 32.7% respectively w.r.t untreated cells. After treatment with EGCG (200 μM), 25.7%, 
8.1%, 9.4% and 19.7% cells composed the G1, S, G2/M and apoptotic cell population. In case of 
Curcumin (25 μM) treatment, 39.6% of cells in G1 phase, 2.6% of cells in S phase, 22.7% of cells 
in G2/M and 24.3% of apoptotic cells were reported.  
 
Figure 6(a): Cell cycle distribution of MCF-7 after treatment with different epigentic modulators for 24 h.  
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MDA-MB-231 cells were also treated with various epigenetic modulators and the cell 
population was assessed after 24 h. In case of controls cells, the percentage of G1, S, G2/M and 
apoptotic cell population were found to be 38.2%, 15.7%, 7.6% and 6.5% respectively. After 
treatment with AZA(15 μM), the percentage of G1, S, G2/M and apoptotic cell population were 
seen to be 28.3%, 5.1%, 8.4% and 16.5% respectively. In case of SAM (15 μM), the population 
of G1, S, G2/M and apoptotic cells is found to be 18.5%, 13.3%, 9.3% and 5.9% respectively. For 
TSA (150 nM), the populations were 14.3%, 6.4%, 3.9% and 33.3% respectively w.r.t untreated 
cells. In case of SFN treatment, 13.2%, 9.3%, 3.9% and 42.7% of cells were found in G1, S, G2/M 
and apoptotic stage respectively w.r.t untreated cells. After EGCG (250 μM) treatment, the 
percentage of G1, S, G2/M and apoptotic cell population were found to be 26.7%, 6.1%, 5.4% and 
17.7%. After treatment with Curcumin (25 μM), 15.7%, 8.1%, 9.4% and 29.7% cells composed 
G1, S, G2/M and apoptotic cell population.  
 
Figure 6(b): Cell cycle distribution of MDA-MB-231 cell population after treatment for 24 h. 
 
From these observations, it is clear that in comparison to control untreated cells; there is a 
decrease in percentage of cell in G1, S, G2/M stages with simultaneous drastic increase in 
apoptotic population after treatment with the epigenetic modulators. TSA, SFN, EGCG and 
curcumin are found to be highly effective in inducing apoptotic cell death with SFN being the 
most potent one. These epigenetic modulators affect all the stages of cell cycle, arresting cell 
progression in each successive stage and ultimately increasing the rate of apoptosis in breast 
cancer.   
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4. Scratch and Migration Assay after drug treatment 
Epigenetic modulators affect wound healing ability of MCF-7 and MDA-MB-231 cells. 
 
The wound healing and cell migratory ability of MCF-& and MDA-MB-231 cells were 
assessed after treatment with epigenetic modulators for 24 h by scratch assay. Both the cell lines 
were treated with IC50 concentration of the epigenetic drugs for 24 h to study their effect on 
cancer cell motility. It is observed that different epigenetic drugs have differential effects on the 
migration ability of both cell lines. MCF-7 cells, being primary stage cell line showed less 
migration in comparison to MDA-MB-231 cells which are highly metastatic and have high 
migratory ability. The results of scratch assay are given below (Fig. 7). 
 
Figure 7: Microscopic images showing cell migration and wound healing in MCF-7 and MDA MB-231 cells 
after different with various epigentic drugs for 24 h. 
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5. Relative Gene Expression Analysis after drug treatment by RT-PCR  
             The effect of the epigenetic modulators on the expression of HH pathway genes in both 
MCF-7 and MDA-MB-231 cells was determined by the quantitative analysis of mRNA after 
treatment. In case of MCF-7, the transcript level of SHH shows increase of 14.1 fold after AZA 
(15 μM), of 11.3 fold after SAM (15 μM), of 8.3 fold after TSA (100 nM), of 9.8 fold after SFN 
(10 μM), of 12.5 fold after EGCG (200 μM) and 5.6 fold after CR (25 μM) treatment. Similarly 
for PTCH, the level of transcript increases by 5.4 fold after AZA, 3.4 fold after SAM, 2.5 fold 
after TSA, 2.8 after SFN, 6.1 fold after EGCG and 5.8 fold after CR treatment. There is also 
similar increase in transcript level for SMO such as 2.1 fold after AZA, 2.9 fold after SAM, 1.9 
fold after TSA, 1.5 fold after SFN, 3.4 fold after EGCG and 1.8 fold after CR treatment. The 
increase in GLI1 level after treatment with AZA is 1.8 fold, after SAM is 3.2 fold, after TSA is 
2.4 fold, after SFN is 1.9 fold, after EGCG is 4.1 fold and after CR treatment is 1.1 fold. 
 
Figure 8(a): Relative fold change in SHH gene expression w.r.t β-actin in variously treated breast cancer cells  
 
Figure 8(b): Relative fold change in PTCH expression w.r.t β-actin in variously treated breast cancer  cells  
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Figure 8(c): Relative fold change in SMO gene expression w.r.t β-actin in variously treated breast cancer cells  
 
Figure 8(d): Relative fold change in GLI1 gene expression w.r.t β-actin in variously treated breast cancer cells  
  
Simillarly, after treatment with the various modulators there is a slight increase in 
expression of HH pathway genes in MDA-MB-231 cells also. The transcript level of SHH 
increases by 16.2 fold after AZA, by 10.6 fold after SAM, by 9.1 fold after SFN, by 13.4 fold 
after EGCG and 6.1 fold after CR treatment. For PTCH, the transcript level shows an increase of 
13.5 fold after AZA, 12.9 fold after SAM, 9.8 fold after TSA, 7.6 fold after SFN, 11.3 fold after 
EGCG and 8.6 fold after CR treatment. Simillarly, SMO transcript levels also show increase by 
1.3 fold after AZA, 2.5 fold after SAM, 3.2 fold after TSA, 1.9 fold after SFN, 4.4 fold after 
EGCG and 2.7 fold after CR treatment. In case of GLI1, there is increase of 9.3 fold after AZA, 
12.5 fold after SAM, 8.2 fold after TSA, 6.9 fold after SFN, 7.4 fold after EGCG and 8.7 fold 
after CR treatment. It is thus clear that, these epigenetic modulators affect the transcript level 
expression of the HH pathway components.  
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CONCLUSION 
 
In this study, we have analyzed the effect of various epigenetic drugs on the gene 
expression status of HH pathway components in MCF-7 and MDA-MB-231 breast cancer cell 
lines. The effect of these modulators on cell growth and survival was also monitored. With 
increasing concentration of drugs, cells showed drastic decrease in cell viability and increased 
rates of apoptosis, indicating that these drugs affect cell growth. Cell viability decreases most 
strongly by treatment with SFN, TSA and CR whereas SAM being a universal methyl donor has 
very little effect on cell viability. After treatment with the epigenetic modulators, percentage of 
condensed nuclei was found to be more in SFN, TSA and Curcumin treated cells in comparison 
to control untreated cells indicating that they have higher concentration of apoptotic cells. 
Scratch and Migration assay showed that TSA, SFN and CR treated cells exhibited the least 
wound healing ability, hence can be considered to be highly effective drugs against breast cancer 
cells. In FACS analysis, it was observed that TSA, CR and SFN treated cells showed the highest 
rates of apoptosis. The relative gene expression analysis showed that the level of expression of 
the four HH component genes varied according to the type of drug treatment. Thus, it is seen that 
epigenetic drugs affect the gene expression of HH signaling pathway components as well as 
affect cell growth and viability of breast cancer cells. Further studies on protein expression in 
drug treated cells will help to substantiate these observations. The deciphering of the epigenetic 
machinery behind HH pathway deregulation in cancer will be a novel approach to inhibit or 
restrict this pathway in cancer.  
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